Fig. 2From: 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life settingClinical outcomes on central retinal thickness over 24 months. CRT was even better at 24 months than 12 monthsBack to article page